Business Description
Ikena Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US45175G1085
Description
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.44 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.28 | |||||
| Beneish M-Score | -7.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.3 | |||||
| 3-Year EBITDA Growth Rate | -11.7 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | -19.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.91 | |||||
| 9-Day RSI | 37.61 | |||||
| 14-Day RSI | 38.4 | |||||
| 6-1 Month Momentum % | 1.79 | |||||
| 12-1 Month Momentum % | -24.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.32 | |||||
| Quick Ratio | 15.32 | |||||
| Cash Ratio | 14.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.7 | |||||
| Shareholder Yield % | -3.54 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -9755.24 | |||||
| Net Margin % | -9043.85 | |||||
| FCF Margin % | -9341.88 | |||||
| ROE % | -39.34 | |||||
| ROA % | -33.61 | |||||
| ROIC % | -374.12 | |||||
| ROC (Joel Greenblatt) % | -914.6 | |||||
| ROCE % | -38.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 109.29 | |||||
| PB Ratio | 0.55 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | 0.76 | |||||
| EV-to-Forward-EBIT | -0.41 | |||||
| EV-to-EBITDA | 0.77 | |||||
| EV-to-Forward-EBITDA | -0.31 | |||||
| EV-to-Revenue | -74.43 | |||||
| EV-to-Forward-Revenue | 0.96 | |||||
| EV-to-FCF | 0.8 | |||||
| Price-to-Net-Current-Asset-Value | 0.58 | |||||
| Price-to-Net-Cash | 0.6 | |||||
| Earnings Yield (Greenblatt) % | 131.58 | |||||
| FCF Yield % | -83.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IKNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ikena Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.659 | ||
| EPS (TTM) ($) | -1.22 | ||
| Beta | 0.74 | ||
| Volatility % | 61.98 | ||
| 14-Day RSI | 38.4 | ||
| 14-Day ATR ($) | 0.095739 | ||
| 20-Day SMA ($) | 1.656 | ||
| 12-1 Month Momentum % | -24.34 | ||
| 52-Week Range ($) | 1.22 - 2.29 | ||
| Shares Outstanding (Mil) | 48.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ikena Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ikena Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ikena Oncology Inc Frequently Asked Questions
What is Ikena Oncology Inc(IKNA)'s stock price today?
The current price of IKNA is $1.53. The 52 week high of IKNA is $2.29 and 52 week low is $1.22.
When is next earnings date of Ikena Oncology Inc(IKNA)?
The next earnings date of Ikena Oncology Inc(IKNA) is 2025-03-12 Est..
Does Ikena Oncology Inc(IKNA) pay dividends? If so, how much?
Ikena Oncology Inc(IKNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers